Actinium Pharmaceuticals Inc (ATNM) Short Interest Update
Actinium Pharmaceuticals Inc (NYSE:ATNM) saw a large growth in short interest in September. As of September 30th, there was short interest totalling 2,109,473 shares, a growth of 43.5% from the September 15th total of 1,469,849 shares. Approximately 4.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,513,728 shares, the short-interest ratio is presently 1.4 days.
Actinium Pharmaceuticals (NYSE:ATNM) traded down 3.97% during mid-day trading on Tuesday, hitting $1.16. The stock had a trading volume of 949,560 shares. Actinium Pharmaceuticals has a 1-year low of $1.12 and a 1-year high of $3.50. The stock has a 50 day moving average of $1.64 and a 200-day moving average of $1.77. The firm’s market cap is $55.35 million.
About Actinium Pharmaceuticals
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/actinium-pharmaceuticals-inc-atnm-short-interest-update.html
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.